What is Prime Medicine's stock issuance proceeds?

Prime Medicine (PRME) reported stock issuance proceeds of $393K in Q1 2026.

What is the long-term trend for Prime Medicine's stock issuance proceeds?

Over 2 years (2022 to 2025), Prime Medicine's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $219K to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Prime Medicine PRME Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Intellia TherapeuticsNTLA

$194.6M—

CRISPR TherapeuticsCRSP

-$722K-108%

Beam TherapeuticsBEAM

$2.03M+182%

RegenxbioRGNX

$146K-2.7%

Sarepta Therapeutics, Inc.SRPT

$241K-98.5%

Sana BiotechnologySANA

$59K-94.8%

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's stock issuance proceeds?: Prime Medicine (PRME) reported stock issuance proceeds of $393K in Q1 2026.
What is the long-term trend for Prime Medicine's stock issuance proceeds?: Over 2 years (2022 to 2025), Prime Medicine's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $219K to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.